View Older Stories View More Recent Stories
-
Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option
-
Form SCHEDULE 13D/A ARS Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Drugmakers pressured with Trump tariffs after price‑cut talks faltered
-
Form SCHEDULE 13D/A PepGen Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
RA Capital Management Funds Expansion of ARS Pharma Commercial Activity, Expands Portfolio of Financing Solutions for Innovative Healthcare Companies
-
Star Therapeutics Announces Oversubscribed $125 Million Series D Financing
-
ARS Pharmaceuticals secures $250 million loan facility for neffy expansion
-
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®
-
Nobel Laureate Headlines Global Discussion in Cell & Gene Therapy in London
-
Sparrow Pharmaceuticals Announces $95 Million Series B Financing to Advance Targeted Therapy for Type 2 Diabetes
-
Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G LB PHARMACEUTICALS INC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Navigator Medicines Announces Positive Phase 1a Data from its Program of Potential Best-in-Class Bispecific Antibodies; NAV-240 Poised for Further Development in Inflammatory Disorders and Autoimmune
-
ProofPilot Announces Inaugural CORE Symposium for Clinical Operations Leaders
-
Benchmark Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE) Following PIPE Transaction
-
Form SCHEDULE 13D/A Mineralys Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Belite Bio raises up to $275 million in private placement
-
Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors
-
CellCentric Announces First Patients Dosed with Inobrodib in Combination with Bispecific Antibodies in Multiple Myeloma
-
Form SCHEDULE 13G Invivyd, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form N-PX RA CAPITAL MANAGEMENT, For: Jun 30
-
Form SCHEDULE 13G/A Adagio Medical Holdings, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Ex-Amazon Robotics Leaders at Reframe Systems Raise $20M to Scale Microfactories to Tackle America’s Housing Crisis
-
Invivyd closes $57.5 million public offering with full underwriter option
-
Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional Shares
-
Form SCHEDULE 13G/A CervoMed Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G ASSEMBLY BIOSCIENCES, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Verona Pharma plc Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A UroGen Pharma Ltd. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Taysha Gene Therapies, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A SUTRO BIOPHARMA, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A SERA PROGNOSTICS, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13D/A Solid Biosciences Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A RHYTHM PHARMACEUTICALS, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Protara Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A GH Research PLC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Day One Biopharmaceutica Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A CervoMed Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Boundless Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Astria Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Alector, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Adagio Medical Holdings, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Jun 30
-
Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI
-
Lilly signs up to $1.3 billion deal with Superluminal for obesity drugs
-
Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity
-
Form SCHEDULE 13D/A Cidara Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Assembly Biosciences prices $175 million equity financing with Gilead
-
Assembly Biosciences Announces Pricing of $175 Million in Equity Financings
-
Be Bio Announces First Participant Dosed in BeCoMe-9 Trial of BE-101 in Hemophilia B
